Pliant Therapeutics, Inc.
PLRX Healthcare Biotechnology
Pliant Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $1.6 million, down 83.7% from fiscal 2022. In the quarter to June 2026, EPS grew 49.3% and free cash flow grew 68.6%, each against the same quarter a year earlier.
Follow PLRX
Pliant Therapeutics, Inc. (PLRX) EV/Sales
As of 16 October 2026, Pliant Therapeutics, Inc. (PLRX) trades at a EV/Sales of −14.3×. Over the past ten years it has ranged from −48.5× (March 2025) to 133× (January 2024); the current reading is higher than 18% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | 113× | 130.36% |
| FY2022 | 49.3× | 29.21% |
| FY2021 | 38.1× | 666.21% |
| FY2020 | 5.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2023 | 105× | 10.86% |
| Mar 2023 | 94.6× | 92.00% |
| Dec 2022 | 49.3× | (23.68%) |
| Sep 2022 | 64.5× | 367.25% |
| 11 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TENX Tenax Therapeutics, Inc. compare | −142× |
| PLRX Pliant Therapeutics, Inc. | −14.3× |
| FBIO Fortress Biotech, Inc. compare | −1.4× |
| BMEA Biomea Fusion, Inc. compare | n/m |
| CING Cingulate Inc. compare | n/m |
| APLM Apollomics Inc. compare | n/m |
| XLO Xilio Therapeutics, Inc. compare | 0.6× |
| CNTB Connect Biopharma Holdings Limited Sponsored ADR compare | 8.6× |
| GANX Gain Therapeutics, Inc. compare | 211× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)